Gemtuzumab (Anti-Siglec-3/CD33) is a recombinant humanized monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid.
Gemtuzumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to CD33 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Gemtuzumab-SAP eliminates cells expressing human CD33. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: gemtuzumab, siglec, siglec-3, anti-siglec-3, CD33, leukemic myeloblasts, acute myeloid leukemia, AML, streptavidin, saporin, immunotoxin